Therefore, reducing Gd-IgA1 production by inhibiting mucosal B-lymphocyte activation and Peyer plaque proliferation can also become a new way to treat primary IgA nephropathy (23). The gene discussed is IGHA1; the disease is IgA glomerulonephritis.